fatty acid oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
The Emergence of Russian Panslavism, 1856-1870 (Columbia University Press, 1956) Riasanovsky, Nicholas Valentine (2006). A History of Russia (6th ed.). US: Oxford University Press. p. 450. ISBN 978-0-19-512179-7. Retrieved 22 September 2018. Snyder, Louis L. Encyclopedia of Nationalism (1990) pp 309–315. Tobolka Z. Der Panslavismus, Zeitschrift fur Politik, 6 (1913) Vyšný, Paul. Neo-Slavism and the Czechs, 1898-1914 (Cambridge University Press, 1977). Yiǧit Gülseven, Aslı (26 October 2016). "Rethinking Russian pan-Slavism in the Ottoman Balkans: N.P. Ignatiev and the Slavic Benevolent Committee (1856–77)". Middle Eastern Studies. 53 (3): 332–348. doi:10.1080/00263206.2016.1243532. hdl:11693/37207. ISSN 0026-3206. S2CID 220378577. "Pan-Slavism" in Columbia Encyclopedia
== History == Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA. Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories, and injection fluid. A sustained release formulation, sold as Ketodur, exists in some countries and contains 10 or 25 mg ketobemidone.
=== Halides === Protactinium(V) fluoride is a white compound that forms tetragonal crystals, isomorphic to β-UF5. Protactinium(V) chloride forms yellow crystals where protactinium ions are arranged in pentagonal bipyramids and coordinated by 7 other ions. The coordination changes to octahedral in the brown protactinium(V) bromide, but is unknown for protactinium(V) iodide. The protactinium coordination in all its tetrahalides is 8, but the arrangement is square antiprismatic in protactinium(IV) fluoride and dodecahedral in the chloride and bromide. Brown-colored protactinium(III) iodide has been reported, where protactinium ions are 8-coordinated in a bicapped trigonal prismatic arrangement.
=== Elderly === Zopiclone, similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs, causes impairments in body balance and standing steadiness in individuals who wake up at night or the next morning. Falls and hip fractures are frequently reported. The combination with alcohol consumption increases these impairments. Partial, but incomplete tolerance develops to these impairments. Zopiclone increases postural sway and increases the number of falls in older people, as well as cognitive side effects. Falls are a significant cause of death in older people. An extensive review of the medical literature regarding the management of insomnia and the elderly found that considerable evidence of the effectiveness and lasting benefits of nondrug treatments for insomnia exist. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics, such as zopiclone, offer few if any advantages in efficacy or tolerability in elderly persons. Newer agents such as the melatonin receptor agonists may be more suitable and effective for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and is discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of nonbenzodiazepine hypnotic drugs remains to be determined.
Sources: en.wikipedia.org
The Canadian Society of Clinical Chemists (CSCC) is a nonprofit scientific society that represents clinical chemists (also known as clinical biochemists) in Canada. The organization aims to advance the practice of clinical chemistry in Canada through the promotion of importance in education, research, and practice, working at the international, national, provincial, and local levels. The CSCC is a full member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which is associated with the International Union of Pure and Applied Chemistry (IUPAC).
The enzyme naringenin 8-dimethylallyltransferase uses dimethylallyl diphosphate and (2S)-naringenin to produce diphosphate and 8-prenylnaringenin. Cunninghamella elegans, a fungal model organism of the mammalian metabolism, can be used to study the naringenin sulfation. In plants, the biosynthetic pathway to anthocyanins continues when the enzyme flavanone 3-dioxygenase inserts a hydroxyl group into the dihydropyran ring:
== Cytokine therapy == Cytokines are proteins produced by many types of cells present within a tumor. They can modulate immune responses. The tumor often employs them to allow it to grow and reduce the immune response. These immune-modulating effects allow them to be used as drugs to provoke an immune response. Two commonly used cytokines are interferons and interleukins. Interleukin-2 and interferon-α are cytokines, proteins that regulate and coordinate the behavior of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as passive cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and melanoma. Interleukin-2 is used in the treatment of melanoma and renal cell carcinoma.
This lowers the temperature of the liquid nitrogen below its boiling point, so that when the specimen is plunged into it, it envelops the specimen closely for a brief period of time and extracts heat from it more efficiently. Even faster cooling can be obtained by plunging specimens into liquid propane or ethane (ethane has been found to be more efficient) cooled very close to their melting points using liquid nitrogen or by slamming the specimen against highly polished liquid nitrogen-cooled metal surfaces made of copper or silver. Secondly, two properties of water itself prevent rapid cryofixation in large specimens. The thermal conductivity of ice is very low compared with that of metals, and water releases of latent heat of fusion as it freezes, defeating rapid cooldown in specimens more than a few micrometres thick.
== Chemistry == L-DOPA, also known as L-3,4-dihydroxyphenylalanine or L-3-hydroxytyrosine, is an aromatic amino acid derived from L-phenylalanine and L-tyrosine. It is a phenethylamine, monoamine, and catecholamine, and is a biological precursor of the neurotransmitters dopamine (3,4-dihydroxyphenethylamine), norepinephrine (3,4,β-trihydroxyphenethylamine), and epinephrine (3,4,β-trihydroxy-N-methylphenethylamine).
Sources: en.wikipedia.org
== Marketing == In the United States, Nestlé used the Nescafé name on its products until the late 1960s. Later, Nestlé introduced a new brand in Canada and the US called Taster's Choice, which supplanted Nescafé for many years. The company continues to sell Taster's Choice as a separate product, branded as superior to Nescafé and higher priced.
=== Classical antiquity === Greco-Roman accounts of what we now know as diabetes primarily describe excessive urination (polyuria). There is no known account of sweetness in early Greco-Roman concepts of the disease. Given the lasting legacy of classical medicine, these descriptions remained highly influential into the Middle Ages in Europe.
Regardless of the IUD type, some potential side effects are similar for all IUDs. Some of these side effects include bleeding pattern changes, expulsion, and pelvic inflammatory disease (especially in the first 21 days after insertion). The occurrence of IUD migration to another location outside of the uterus is rare, with reported rates in medical literature varying between 0.1% and 0.9%. However, when migration occurs, it can lead to serious complications such as uterine perforation and, in rare cases, bladder perforation. Bladder perforation, while uncommon (affecting only 2% of migrated IUDs), can result in symptoms like urinary frequency, hematuria, and stone formation, often necessitating surgical intervention for removal. Regular monitoring and imaging, such as ultrasound or CT scans, are recommended to detect such complications early and ensure timely treatment. A small probability of pregnancy remains after IUD insertion, and when it occurs, there is a greater risk of ectopic pregnancy. Hormonal IUDs confer an increased risk of ovarian cysts. Mirena lists common (less than 1 in 10 women) side effects as including ovarian cysts, painful periods, increased vaginal discharge, headaches and depression. Hormonal IUDs have been associated with psychiatric symptoms, including depression, anxiety, and suicidal ideation, particularly in adolescents and young women, though evidence remains mixed.
=== Australia === In-N-Out Burger has also had other similarly named imitators in Australia that confuse consumers into thinking that the businesses is associated with the Californian-based chain. The company would take the imitators to court for trademark infringement and has opened one-day pop-ups in Sydney in 2012, 2013, 2016, 2017, 2019, and 2022; Brisbane in 2020; Melbourne in 2014 and 2018; and Perth in 2018 and 2022 to preserve their trademark rights. Customers may wait for several hours before the doors open, but the food would run out very quickly, sometimes in less than hour after opening. Although In-N-Out may not have plans to open a permanent location outside its current operating region, the business strategy of having one-day pop-ups is to maintain a business presence in the country under Australian trademark law without opening a permanent restaurant. In-N-Out successfully defended their trademarks and intellectual property rights in Australia in 2020 against Hashtag Burgers Pty Ltd, formerly doing business as "Funk N Burgers" and "Down-N-Out Burger". In 2021, In-N-Out filed a lawsuit against Queensland-based Rich Asians Pty Ltd doing business as "In & Out Aussie Burgers".
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.